EVE Health Group Ltd (ASX:EVE) Share Price Jumps: Key Reasons Explained

Sonal Goyal

03 November 2026 03:09 PM AEDT

EVE Health Group Ltd (ASX:EVE) Share Price Jumps: Key Reasons Explained

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

EVE Health Group shares rose 8.33% to $0.013 in the 3 November 2026 trading session, while the S&P/ASX 200 gained 0.14%.
The patient pathway for the Libbo oral film is operating end to end, with pilot dosing targeted for Q4 2026.
Closing cash was $836,000 at 30 September 2026 with no borrowings.

During the Trading session on 3 November 2026, EVE Health Group Ltd (ASX:EVE) shares rose 8.33% to $0.013. The S&P/ASX 200 (ASX:XJO) was up 0.14%, or 12.50 points, at 8,869.00 at 2:42 pm (GMT+11) on the same day. EVE Health Group is an Australian life sciences company developing pharmaceutical products. Its quarterly activities report, dated 30 October 2026, covers the quarter ended 30 September 2026.

Patient pathway

The patient pathway for the erectile dysfunction oral film, covering education, telehealth, pharmacy fulfilment and home delivery, is operating end to end. The company said access is intended for eligible patients through applicable prescribing pathways, including the Special Access Scheme Category B, where approvals are obtained.

Pilot study

A pilot pharmacokinetic study will compare the film with a registered reference tablet in fasted healthy male participants. Dosing is targeted for Q4 2026, subject to remaining testing and regulatory steps, with results expected in early 2027.

Timeline

Subject to pilot outcomes, EVE is targeting a pivotal bioequivalence study to start in Q1 2027, with a potential registration submission in the second half of 2027.

Pipeline

The reformulation pipeline includes earlier-stage men's health programs and cardio-metabolic work, including an apixaban reformulation in pre-bioequivalence development. Dyspro, the women's health product, is the subject of a case study report on patient experiences.

Financial position

Closing cash was $836,000 with no borrowings. Payments to related parties totalled $67,000. An R&D tax incentive refund is expected in the December quarter.

Sector context

The S&P/ASX 200 gained 0.14% during the session. The company cited an estimated 322 million men affected by erectile dysfunction worldwide in 2025, which is its own estimate.

Risks

Cash of $836,000 is modest against the program outlined, so the studies will depend on further funding or partnering. Pilot results are not yet available and could change the timetable. Partner discussions are preliminary, with no assurance of binding agreements.

What lies ahead

Pilot dosing in Q4 2026, pilot data in early 2027, the pivotal study in Q1 2027 and the R&D tax refund in the December quarter are the next milestones.

Final Word

The quarter showed progress on patient access and a clear pilot timetable, alongside a small cash balance.

FAQs

Q: How did EVE shares trade on 3 November 2026?

A: During the trading session, shares rose 8.33% to $0.013, while the S&P/ASX 200 gained 0.14%.

Q: When is the pilot study expected to start?

A: Dosing is targeted for Q4 2026, with results anticipated in early 2027.

Q: How much cash did EVE have?

A: Closing cash was $836,000 at 30 September 2026 with no borrowings.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.